Immunotherapy and targeted therapy after stomach cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (serplulimab), a targeted HER2 therapy (trastuzumab), and chemotherapy (SOX) after stomach cancer surgery. The goal is to see if this combination reduces the chance of cancer returning in people with HER2-positive stomach cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that is HER2-positive (a specific protein on the cancer cells).
- You have had surgery to remove all visible cancer, and your cancer stage is II or III.
- You are between 18 and 75 years old and are generally able to care for yourself (ECOG 0-1).
- You have adequate blood counts and liver/kidney function (tests will confirm).
- You have not had anti-HER2 targeted therapy before surgery.
- You do not have other active cancers, serious autoimmune conditions, or uncontrolled heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of drugs (including an investigational drug called KN026) for people with HER2-positive stomach cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests whether adding a targeted therapy (anti-HER2) to standard chemotherapy after surgery can improve outcomes for people with early-stage gastric cancer that has high HER2 levels. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This Phase 2 study looks at whether adding serplulimab to trastuzumab and chemotherapy after surgery can lower the chance of stomach cancer coming back. It is for people with HER2-positive stage II–III stomach adenocarcinoma who have already had curative surgery with lymph node removal.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
Hear when a new HER2-positive Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.